Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure

C A J Farquharson, A D Struthers

    Research output: Contribution to journalArticlepeer-review

    40 Citations (Scopus)

    Abstract

    To test whether simply increasing plasma potassium with amiloride would exert any of the same beneficial effects on "surrogate outcome measures" that are seen with spironolactone. The latter has been shown to improve mortality in chronic heart failure, possibly as a result of improvements in endothelial dysfunction, vascular angiotensin converting enzyme (ACE), autonomic function, myocardial fibrosis, ventricular arrhythmias, and QT interval indices.
    Original languageEnglish
    Pages (from-to)475-80
    Number of pages6
    JournalHeart (British Cardiac Society)
    Volume88
    Issue number5
    DOIs
    Publication statusPublished - 2002

    Fingerprint

    Dive into the research topics of 'Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure'. Together they form a unique fingerprint.

    Cite this